{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-037161","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2024-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.439712+00:00","generated_at":"2026-06-04T07:18:25.860415+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Erasca reports FY2023 net loss $125M, cash $322M; clinical updates for naporafenib and ERAS-801","bullets":["Net loss $125M ($0.83/share) for FY2023 vs $242.8M ($1.99/share) in prior year; R&D expenses $103.8M.","Cash, equivalents, marketable securities $322M as of Dec 31, 2023, down from $435.6M.","Gained FDA Fast Track Designation for naporafenib + trametinib in NRASm melanoma; planned Phase 3 SEACRAFT-2 initiation H1 2024.","Entered clinical trial collaboration with Novartis for trametinib supply for naporafenib trials at no cost.","Multiple data readouts expected in 2024 for naporafenib (SEACRAFT-1), ERAS-007 (HERKULES-3), ERAS-801 (THUNDERBBOLT-1)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-037161","json":"https://secwatch.observer/filing/0000950170-24-037161.json","markdown":"https://secwatch.observer/filing/0000950170-24-037161.md","text":"https://secwatch.observer/filing/0000950170-24-037161.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000095017024037161/0000950170-24-037161-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000095017024037161/eras-20240327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:18:25.860415+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bc5540ed3fa0869c1d49a90526771a778fe08c3c","claim":"Erasca, Inc. reported financial results for the fiscal quarter and full year ended December 31, 2023.","evidence_excerpt":"On March 27, 2024, Erasca, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761918/000095017024037161/0000950170-24-037161-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}